197 related articles for article (PubMed ID: 7909868)
1. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia.
Lilleyman JS; Lennard L
Lancet; 1994 May; 343(8907):1188-90. PubMed ID: 7909868
[TBL] [Abstract][Full Text] [Related]
2. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.
Lennard L; Lilleyman JS; Van Loon J; Weinshilboum RM
Lancet; 1990 Jul; 336(8709):225-9. PubMed ID: 1973780
[TBL] [Abstract][Full Text] [Related]
3. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
4. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L
J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
[TBL] [Abstract][Full Text] [Related]
5. Childhood lymphoblastic leukaemia: sex difference in 6-mercaptopurine utilization.
Lilleyman JS; Lennard L; Rees CA; Morgan G; Maddocks JL
Br J Cancer; 1984 Jun; 49(6):703-7. PubMed ID: 6587901
[TBL] [Abstract][Full Text] [Related]
6. Variable mercaptopurine metabolism in children with leukaemia: a problem of non-compliance?
Davies HA; Lennard L; Lilleyman JS
BMJ; 1993 May; 306(6887):1239-40. PubMed ID: 8499854
[No Abstract] [Full Text] [Related]
7. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
Lennard L; Cartwright CS; Wade R; Richards SM; Vora A
Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
Balis FM; Holcenberg JS; Poplack DG; Ge J; Sather HN; Murphy RF; Ames MM; Waskerwitz MJ; Tubergen DG; Zimm S; Gilchrist GS; Bleyer WA
Blood; 1998 Nov; 92(10):3569-77. PubMed ID: 9808549
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
Erb N; Harms DO; Janka-Schaub G
Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose.
Welch J; Lennard L; Morton GC; Lilleyman JS
Ther Drug Monit; 1997 Aug; 19(4):382-5. PubMed ID: 9263376
[TBL] [Abstract][Full Text] [Related]
11. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia.
Lennard L; Gibson BE; Nicole T; Lilleyman JS
Arch Dis Child; 1993 Nov; 69(5):577-9. PubMed ID: 8257179
[TBL] [Abstract][Full Text] [Related]
12. Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia.
Chrzanowska M; Kolecki P; Duczmal-Cichocka B; Fiet J
Eur J Pharm Sci; 1999 Aug; 8(4):329-34. PubMed ID: 10425383
[TBL] [Abstract][Full Text] [Related]
13. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance?
Lennard L; Welch J; Lilleyman JS
Br J Cancer; 1995 Oct; 72(4):1004-6. PubMed ID: 7547211
[TBL] [Abstract][Full Text] [Related]
14. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
[TBL] [Abstract][Full Text] [Related]
15. 6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia.
Schmiegelow K; Bruunshuus I
Cancer Chemother Pharmacol; 1990; 26(4):288-92. PubMed ID: 2369793
[TBL] [Abstract][Full Text] [Related]
16. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia.
Lennard L; Lilleyman JS
J Clin Oncol; 1989 Dec; 7(12):1816-23. PubMed ID: 2585022
[TBL] [Abstract][Full Text] [Related]
17. Disturbance of 6-mercaptopurine metabolism by cotrimoxazole in childhood lymphoblastic leukaemia.
Rees CA; Lennard L; Lilleyman JS; Maddocks JL
Cancer Chemother Pharmacol; 1984; 12(2):87-9. PubMed ID: 6607783
[TBL] [Abstract][Full Text] [Related]
18. Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells.
Lennard L; Maddocks JL
J Pharm Pharmacol; 1983 Jan; 35(1):15-8. PubMed ID: 6131958
[TBL] [Abstract][Full Text] [Related]
19. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.
Vora A; Mitchell CD; Lennard L; Eden TO; Kinsey SE; Lilleyman J; Richards SM; ;
Lancet; 2006 Oct; 368(9544):1339-48. PubMed ID: 17046466
[TBL] [Abstract][Full Text] [Related]
20. Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia.
Innocenti F; Danesi R; Favre C; Nardi M; Menconi MC; Di Paolo A; Bocci G; Fogli S; Barbara C; Barachini S; Casazza G; Macchia P; Del Tacca M
Ther Drug Monit; 2000 Aug; 22(4):375-82. PubMed ID: 10942174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
